Global Travel Media » Blog Archive » Rhinomed and Boc Partner to Bring Sleep To Pharmacies

Home » Lifestyle » Currently Reading:

Rhinomed and Boc Partner to Bring Sleep To Pharmacies

December 10, 2016 Lifestyle No Comments Email Email

BOC Limited (BOC) and Australian sleep innovator Rhinomed Ltd are setting their sights on boosting the Pharmacist’s role in sleep.

The Companies want to empower consumers to take their sleep seriously and obtain help easily and affordably. Equipping Pharmacists and GPs in their communities to play a greater role in identifying sleep issues is the prime focus of both Rhinomed and BOC. Key to this is ensuring Pharmacists have greater access to sleep related solutions, technologies and information in order to help people with sleeping concerns.

The new relationship will see BOC take on responsibility for distribution of Rhinomed’s Mute nasal stenting technology – designed to alleviate night-time congestion and reduce snoring – in Australia and New Zealand.

The Mute brand has steadily attracted a strong and growing following amongst consumers and clinicians globally. Since its initial launch in early 2015, it has been adopted by leading clinicians in the US and the UK and is sold in the iconic pharmacy chain Boots in the UK and through Walgreens, Duane Reade and CVS in the US. Mute is one of only a few Australian brands to achieve this milestone.

“Mute is the only adjustable intranasal stent on the market. It’s an anatomically inspired, elegantly engineered solution that delivers a better fit, feel and outcome for the 1 in 4 people who suffer from nasal congestion and the almost 1 in 2 who snore,” says Michael Johnson, Rhinomed CEO.

“We have been working closely with Sleep Clinicians and the medical community and have listened to the significant feedback around the importance of nasal air flow in dealing with patient compliance of both CPAP and oral devices, such as mandibular splints. What they are telling us is that Mute is the perfect companion piece for these existing solutions,” says Johnson.

For BOC, as one of the leading suppliers of Sleep solutions in Australia, the Rhinomed deal was an obvious step. Colin Smith, Head of Healthcare at BOC said: “We firmly believe that adding Mute to our solution set allows Pharmacists and GP’s to open up conversations earlier and allow the pharmacist, the GP and the sleep specialist to work closely together to offer a better solution to patients. Mute is an inexpensive way to start that conversation which makes it a perfect fit for us.”

As Johnson outlines: “Mute is unique. It is an Australian developed technology that has also taken into consideration how important it is to facilitate a conversation between a consumer and a pharmacist and a patient and their clinician. All too often great medical technologies are presented to consumers in an intimidating manner. Our technology is presented in a way that allows it to open up very real, authentic and genuine conversations with consumers and patients about how they sleep.”

The distribution agreement will see BOC distribute Rhinomed’s breathing technologies Mute and Turbine (for sport) across Australia and New Zealand.  BOC will also fulfill and supply all of Rhinomed’s existing contracts within Australia – covering over 700 pharmacies currently stocking the product, as well as online sales.

The new arrangement will strengthen Rhinomed’s existing footprint in pharmacies and sleep and dental clinics and will open up new channels to include hospitals and medical practices.

Comment on this Article:

Time limit is exhausted. Please reload CAPTCHA.

Platinium Partnership


Elite Partnership Sponsors


Premier Partnership Sponsors


Official Media Event Partner


Global travel media endorses the following travel Publication